IonDX Inc. is developing an advanced system to analyze biologic drugs. The current biotherapeutic development cost is extremely high, >$2.5B and 8-10 years to introduce one of these drugs into the market. The firm's technology aims to improve analytical quality and reduce this cost by implementing a highly informative, fast, and reproducible assay. Its patented ion mobility spectrometers can simultaneously measure five important attributes of protein-based drugs: drug concentration, purity, stability and structural conformation of these molecules. It produces quantitative and correlative measurement in <5 minutes with a bench-top instrument. The short time range is rapid enough to introduce it in bioprocess environment where other technologies are too slow and unreliable. IonDXâs technology, being amenable to other analytical interfaces and automation, can fit into typical biotherapeutic high-throughput workflows, providing unique capability to reduce time and effort to bring a biotherapeutic to market
